Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study
Background. Reversible P2Y12 inhibition can be obtained with cangrelor administered intravenously. More experience with cangrelor use in acute PCI with unknown bleeding risk is needed. Objectives. To describe real-world use of cangrelor including patient and procedure characteristics and patient out...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2023/3197512 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546772838252544 |
|---|---|
| author | Troels Thim Lars Jakobsen Rebekka Vibjerg Jensen Nicolaj Støttrup Ashkan Eftekhari Erik Lerkevang Grove Sanne Bøjet Larsen Jacob Thorsted Sørensen Steen Carstensen Sahar Amiri Karsten Tange Veien Evald Høj Christiansen Christian Juhl Terkelsen Michael Maeng Steen Dalby Kristensen |
| author_facet | Troels Thim Lars Jakobsen Rebekka Vibjerg Jensen Nicolaj Støttrup Ashkan Eftekhari Erik Lerkevang Grove Sanne Bøjet Larsen Jacob Thorsted Sørensen Steen Carstensen Sahar Amiri Karsten Tange Veien Evald Høj Christiansen Christian Juhl Terkelsen Michael Maeng Steen Dalby Kristensen |
| author_sort | Troels Thim |
| collection | DOAJ |
| description | Background. Reversible P2Y12 inhibition can be obtained with cangrelor administered intravenously. More experience with cangrelor use in acute PCI with unknown bleeding risk is needed. Objectives. To describe real-world use of cangrelor including patient and procedure characteristics and patient outcomes. Methods. We performed a single-centre, retrospective, and observational study including all patients treated with cangrelor in relation to percutaneous coronary intervention at Aarhus University Hospital during the years 2016, 2017, and 2018. We recorded procedure indication and priority, the indications for cangrelor use, and patient outcomes within the first 48 hours after initiation of cangrelor treatment. Results. We treated 991 patients with cangrelor in the study period. Of these, 869 (87.7%) had an acute procedure priority. Among acute procedures, patients were mainly treated for STEMI (n = 723) and the remaining were treated for cardiac arrest and acute heart failure. Use of oral P2Y12 inhibitors prior to percutaneous coronary intervention was rare. Fatal bleeding events (n = 6) were only observed among patients undergoing acute procedures. Stent thrombosis was observed in two patients receiving acute treatment for STEMI. Thus, cangrelor can be used in relation to PCI under acute circumstances with advantages in terms of clinical management. The benefits and risks, in terms of patient outcomes, should ideally be assessed in randomized trials. |
| format | Article |
| id | doaj-art-e295892529d64a0db3b6cde00c2b5231 |
| institution | Kabale University |
| issn | 2090-0597 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiology Research and Practice |
| spelling | doaj-art-e295892529d64a0db3b6cde00c2b52312025-02-03T06:47:22ZengWileyCardiology Research and Practice2090-05972023-01-01202310.1155/2023/3197512Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational StudyTroels Thim0Lars Jakobsen1Rebekka Vibjerg Jensen2Nicolaj Støttrup3Ashkan Eftekhari4Erik Lerkevang Grove5Sanne Bøjet Larsen6Jacob Thorsted Sørensen7Steen Carstensen8Sahar Amiri9Karsten Tange Veien10Evald Høj Christiansen11Christian Juhl Terkelsen12Michael Maeng13Steen Dalby Kristensen14Department of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyEmergency DepartmentDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyBackground. Reversible P2Y12 inhibition can be obtained with cangrelor administered intravenously. More experience with cangrelor use in acute PCI with unknown bleeding risk is needed. Objectives. To describe real-world use of cangrelor including patient and procedure characteristics and patient outcomes. Methods. We performed a single-centre, retrospective, and observational study including all patients treated with cangrelor in relation to percutaneous coronary intervention at Aarhus University Hospital during the years 2016, 2017, and 2018. We recorded procedure indication and priority, the indications for cangrelor use, and patient outcomes within the first 48 hours after initiation of cangrelor treatment. Results. We treated 991 patients with cangrelor in the study period. Of these, 869 (87.7%) had an acute procedure priority. Among acute procedures, patients were mainly treated for STEMI (n = 723) and the remaining were treated for cardiac arrest and acute heart failure. Use of oral P2Y12 inhibitors prior to percutaneous coronary intervention was rare. Fatal bleeding events (n = 6) were only observed among patients undergoing acute procedures. Stent thrombosis was observed in two patients receiving acute treatment for STEMI. Thus, cangrelor can be used in relation to PCI under acute circumstances with advantages in terms of clinical management. The benefits and risks, in terms of patient outcomes, should ideally be assessed in randomized trials.http://dx.doi.org/10.1155/2023/3197512 |
| spellingShingle | Troels Thim Lars Jakobsen Rebekka Vibjerg Jensen Nicolaj Støttrup Ashkan Eftekhari Erik Lerkevang Grove Sanne Bøjet Larsen Jacob Thorsted Sørensen Steen Carstensen Sahar Amiri Karsten Tange Veien Evald Høj Christiansen Christian Juhl Terkelsen Michael Maeng Steen Dalby Kristensen Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study Cardiology Research and Practice |
| title | Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study |
| title_full | Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study |
| title_fullStr | Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study |
| title_full_unstemmed | Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study |
| title_short | Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study |
| title_sort | real world experience with cangrelor as adjuvant to percutaneous coronary intervention a single centre observational study |
| url | http://dx.doi.org/10.1155/2023/3197512 |
| work_keys_str_mv | AT troelsthim realworldexperiencewithcangrelorasadjuvanttopercutaneouscoronaryinterventionasinglecentreobservationalstudy AT larsjakobsen realworldexperiencewithcangrelorasadjuvanttopercutaneouscoronaryinterventionasinglecentreobservationalstudy AT rebekkavibjergjensen realworldexperiencewithcangrelorasadjuvanttopercutaneouscoronaryinterventionasinglecentreobservationalstudy AT nicolajstøttrup realworldexperiencewithcangrelorasadjuvanttopercutaneouscoronaryinterventionasinglecentreobservationalstudy AT ashkaneftekhari realworldexperiencewithcangrelorasadjuvanttopercutaneouscoronaryinterventionasinglecentreobservationalstudy AT eriklerkevanggrove realworldexperiencewithcangrelorasadjuvanttopercutaneouscoronaryinterventionasinglecentreobservationalstudy AT sannebøjetlarsen realworldexperiencewithcangrelorasadjuvanttopercutaneouscoronaryinterventionasinglecentreobservationalstudy AT jacobthorstedsørensen realworldexperiencewithcangrelorasadjuvanttopercutaneouscoronaryinterventionasinglecentreobservationalstudy AT steencarstensen realworldexperiencewithcangrelorasadjuvanttopercutaneouscoronaryinterventionasinglecentreobservationalstudy AT saharamiri realworldexperiencewithcangrelorasadjuvanttopercutaneouscoronaryinterventionasinglecentreobservationalstudy AT karstentangeveien realworldexperiencewithcangrelorasadjuvanttopercutaneouscoronaryinterventionasinglecentreobservationalstudy AT evaldhøjchristiansen realworldexperiencewithcangrelorasadjuvanttopercutaneouscoronaryinterventionasinglecentreobservationalstudy AT christianjuhlterkelsen realworldexperiencewithcangrelorasadjuvanttopercutaneouscoronaryinterventionasinglecentreobservationalstudy AT michaelmaeng realworldexperiencewithcangrelorasadjuvanttopercutaneouscoronaryinterventionasinglecentreobservationalstudy AT steendalbykristensen realworldexperiencewithcangrelorasadjuvanttopercutaneouscoronaryinterventionasinglecentreobservationalstudy |